Skip to main content
Clinical Trials/NCT03493880
NCT03493880
Recruiting
Not Applicable

The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study

Peking University1 site in 1 country600 target enrollmentSeptember 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Cancer
Sponsor
Peking University
Enrollment
600
Locations
1
Primary Endpoint
Pathological response
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.

Detailed Description

The immune (systemic inflammation) index includes: NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic Score); PI (Prognostic Index); The nutrition index includes: NRS2002; PNI (Prognostic Nutrition Index);

Registry
clinicaltrials.gov
Start Date
September 1, 2015
End Date
September 1, 2025
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Peking University
Responsible Party
Principal Investigator
Principal Investigator

Shuang-xi Li

Associate Chief Surgeon

Peking University

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed adenocarcinoma
  • Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy
  • Diagnosed clinical advanced gastric cancer or esophagogastric cancer

Exclusion Criteria

  • Lack of immuno-nutrition data

Outcomes

Primary Outcomes

Pathological response

Time Frame: One month after surgery

Pathological response

Secondary Outcomes

  • 3-years disease-free survival(Three years after surgery)
  • yp TNM Stage(One month after surgery)
  • Postoperative morbidity(One month after surgery)
  • 3-years overall survival(Three years after surgery)

Study Sites (1)

Loading locations...

Similar Trials